ERBB2 and breast cancer: For an erbB2 model, we used a truncated form of Neu [26],[27] that models a form of erbB2 lacking the extracellular domain present in approximately 30% of HER2-positive breast cancer patients, for whom it is associated with a worse prognosis [58].